Xylocaine was released commercially at the end of the 1940s as the world was recovering from the effects of World War II. Anaesthesia, long regarded as an inferior specialty, was finally being properly acknowledged, and pharmaceutical companies were maturing with more aggressive branding and marketing. Launched into this environment, xylocaine was to have farreaching implications in both the medical and corporate world.
Xylocaine was undoubtedly a significant development in anaesthesia. When Alfred Lee was asked to describe the most significant advances to have taken place in his lifetime, he listed the discovery of xylocaine among the top five.
The reason is that it was the first reasonably efficient and non-toxic local analgesia drug to appear, so that when it became available after 1949, many techniques of local anaesthesia were taken off the shelf to which they had been banished, not because the techniques of injection were faulty, but because there was no really satisfactory drug on the market to inject. For the small Swedish company, Astra, xylocaine was the drug which led its expansion around the world and made it the company we all recognize today. But xylocaine nearly fell at the first hurdle.
All the human and animal testing prior to release had been positive and toxicity tests had allowed safe dosages to be recommended. One great advantage of xylocaine was its lack of tissue irritation, so the early reports that it was causing severe tissue swelling and pain in some dental patients came as a great surprise. Bengt Lundqvist and Nils Löfgren, the developers of the drug, examined these reports and Lundqvist visited the dentists concerned. He discovered that the dentists were drawing up metal syringes of xylocaine early in the day and merely changing needles between cases. Consequently the solution was sitting for hours in contact with the metal. It was clear that this was a possible cause for the problem as all the trials had been performed using glass syringes. Laboratory tests confirmed that the acid xylocaine solution was causing leeching of copper, nickel and tin from the metal and the problem was easily fixed with a change to glass syringes. The rapid investigation of this problem prevented it having any lasting impact on the release of xylocaine, but its effect on Nils Lögren was more devastating. He had seen the side-effect as a personal failure and became increasingly depressed and irritable. It was a pattern that was to reoccur until he eventually took his own life some years later.
Xylocaine was released in Sweden in January 1948 in three strengths; 0.5%, 1% and 2%, all with and without adrenaline.
Within a year, two out of every three dentists had changed from procaine to xylocaine and sales rose rapidly. In Europe the product was licensed to various agents and was similarly successful but there were many problems elsewhere. In the UK the company licensed to sell xylocaine packaged it in England using the raw material from Sweden. Their methods were inefficient and they could not compete with PMC, the local suppliers of procaine. Then, to add to the problem, the U.K. patent office voided the patent due to some legal technicalities. PMC then copied xylocaine and launched it as Xylotox. Despite much legal wrangling there was little that Astra could do except compete with this product and in 1957 they began a fierce marketing campaign to promote their own product in the U.K. The product was repackaged in a range of cartridges and bottles, colourful labels and brochures were developed and discounts were offered to the dental schools for bulk purchases. It was a marketing phenomenon that is now part of our daily life but was quite novel at the time. The strategy succeeded and Astra ultimately acquired PMC and eliminated the competition.
It was a similar story in Australia where a domestic company managed to bypass the patent to manufacture its own product, Nurocain. Astra set up its own company within Australia in 1957 so that it could manufacture and compete locally and bought out the opposition within ten years.
In the U.S.A. the launch of xylocaine was entirely based on dental usage. One of Astra's managers from Sweden, Börje Jalar, moved to the U.S.A. to supervise the operation and personally surveyed the dentists of Boston.
We trotted around the streets of Boston ... carrying a portmanteau full of Xylocaine cartridges and written documentation ...The reaction was very positive -enormously so, in fact. They had found that they could start drilling almost immediately after giving the local anaesthetic injection. With the old drugs the patients had to sit and wait 15-20 minutes for the anaesthesia to take effect. The onset of action was also more certain. Even the dental nurses were enthusiastic. Shortly after its successful launch in the U.S.A., Jalar received an order from the Defense Department for 10 million dental cartridges for use in the Korean War. Just as production was gearing up to meet the order it was cancelled by the Pentagon who were not convinced that the new drug was superior or warranted the extra expense. Jalar went straight to Washington to seek an explanation and managed to apply a dollop of xylocaine ointment into the mouth of the officer in charge. Unable to talk properly due to the intense anaesthesia, he signed the order.
Xylocaine was soon widely accepted by the medical community. By 1950, Hanson and colleagues in Baltimore had reported 785 patients anaesthetized with xylocaine. They performed spinals, peridural blocks, local infiltration, saddle blocks and even intravenous analgesia. They concluded that, compared to commonly employed agents, xylocaine had a more rapid onset, produced more profound anaesthesia of longer duration and had a low incidence of local and general side-effects.
Xylocaine rapidly became the drug of choice for all forms of local anaesthesia. Even in ophthalmology a 4% solution was as effective as 2% cocaine. It was found to be useful as an anticonvulsant and an antiarrhythmic and, in 1954, famously cured Pope Pius XIII of hiccoughs.
CHRISTINE BALL, ROD WESTHORPE Geoffrey Kaye Museum of Anaesthetic History

